Evidence map›Paper›PMID 41827038›Full record

ArticleCell communication and signaling : CCS2026

Knockout of PAK1 and PAK4 supresses tumour growth associated with vasculogenic mimicry inhibition through EphA2-VE-cadherin-MCAM pathway.

Arian Ansardamavandi, Chelsea Dumesny, Sarah Ellis, Ching-Seng Ang, Mehrdad Nikfarjam, Hong He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Arian AnsardamavandiDepartment of Surgery, Austin Precinct, The University of Melbourne, 145 Studley Rd, Melbourne, VIC, 3084, Australia.
Chelsea DumesnyDepartment of Surgery, Austin Precinct, The University of Melbourne, 145 Studley Rd, Melbourne, VIC, 3084, Australia.
Sarah EllisOlivia Newton-John Cancer Research Institute, Melbourne, VIC, 3086, Australia.
Ching-Seng AngMass Spectrometry and Proteomics Facility, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, VIC, 3010, Australia.
Mehrdad NikfarjamDepartment of Surgery, Austin Precinct, The University of Melbourne, 145 Studley Rd, Melbourne, VIC, 3084, Australia.
Hong HeDepartment of Surgery, Austin Precinct, The University of Melbourne, 145 Studley Rd, Melbourne, VIC, 3084, Australia. hong.he@unimelb.edu.au.

Funding

Austin Medical Research Foundation 2024-MNAustin Medical Research Foundation 2025-HH
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDA) remains largely refractory to anti-angiogenic strategies, and non-endothelial perfusion mechanisms such as vasculogenic mimicry (VM, endothelial-like channels formed by tumour cells) may sustain tumour progression. Here, we examined whether the combined knockout of p21-activated kinase 1 and 4 (PAK1&4) affects vascular mimicry (VM) programmes in pancreatic cancer. KPC wild-type or PAK1&4 knockout cells were injected subcutaneously into immunodeficient mice. Knockout of PAK1& 4 suppressed tumour growth, associated with VM inhibition, but not endothelial angiogenesis. Knockout of PAK1& 4 reduced tumour expression of VM markers EphA2, VE-cadherin and MCAM, and decreased EphA2⁺VE-cadherin⁺ and EphA2⁺MCAM⁺, CD31

Indexed as

Antigens, CDCadherinsGene Knockout TechniquesNeovascularization, Pathologicp21-Activated KinasesPancreatic NeoplasmsReceptor, EphA2AnimalsCadherin 5Cell Line, TumorCell ProliferationHumansMiceSignal TransductionAntigens, CDCadherin 5Cadherinsp21-Activated KinasesPAK1 protein, humanPAK4 protein, humanReceptor, EphA2EphA2Hypoxiap21-activated kinasesPancreatic ductal adenocarcinomaVasculogenic mimicryVE-cadherin

Identifiers

PMID41827038
PMCPMC13097946

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.